SCHEMBL4691241

SCHEMBL4691241

COc1ccc(NC2=C(c3ccccc3)C(=O)N(Cc3cc(C)on3)C2=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 8/20 0.67
NR1H3 Q13133 8/20 0.67
MAPT P10636 4/20 0.52
RECQL P46063 1/20 0.52
METAP2 P50579 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
GRIN1 Q05586 2/20 0.42
GRIN2B Q13224 2/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
P2RX3 P56373 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
HPGD P15428 1/20 0.40
GSK3B P49841 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4687950 0.81 NR1H2 (0.72) NR1H2NR1H3MAPTMETAP2SMN1; SMN2
SCHEMBL4450601 0.81 NR1H2 (1.00) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL4686588 0.78 NR1H2 (0.85) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL4685907 0.78 NR1H2 (1.00) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL4688601 0.76 NR1H2 (0.78) NR1H2NR1H3MAPTRECQLSMN1; SMN2
SCHEMBL4688066 0.76 NR1H2 (0.80) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL4691707 0.75 NR1H2 (0.76) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL4687894 0.75 NR1H2 (0.76) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL5745530 0.75 NR1H2 (0.78) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL5747584 0.74 NR1H2 (0.61) NR1H2NR1H3MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1646626-B1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2008-07-02 EP claimed
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators ASTRAZENECA AB (SE) 2006-10-19 US claimed
US-7432288-B2 Pyrrole-2,5-dione derivatives as Liver X receptor modulators ASTRAZENECA AB (SE) 2008-10-07 US disclosed
EP-1646626-B1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2008-07-02 EP disclosed
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators ASTRAZENECA AB (SE) 2006-10-19 US disclosed
EP-1646626-A1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS AstraZeneca AB (SE) 2006-04-19 EP disclosed
WO-2005005417-A1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators NR1H2, NR1H3, SREBF2 NR1H2 1/4885NR1H3 2/4885MAPT 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.